The Effect of Ganoderma on Patients With Head-and-neck Cancer

The Effect of Gandoerma Spores Powder Capsules on the Post-treatment Life Quality and Immune Modulation of the Patients With Head-and-neck Cancer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02238587

Enrollment

100

Registered

2014-09-12

Start date

2014-06-30

Completion date

2015-05-31

Last updated

2014-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head-and-neck Cancer

Keywords

Gandoerma Spores Powder Capsules, head-and-neck cancer.

Brief summary

To study the effect of Ganoderma Spores Powder Capsules on the life quality and immunity status of the patients with head-and-neck cancer after complete treatment (including surgery and / or radiotherapy and/or chemotherapy)

Detailed description

Ganoderma is known to modulate immunity and improve health. However, the mechanism is not clear. We hypothesize that patients who have completed standard treatment with/without radiotherapy might require biological modifier such as Ganoderma to improve life quality and immunity status. A total of 100 patients are randomized to study and control groups. In study group, Ganoderma Spores Powder Capsules are given to the patients for 6 weeks, In control group, only placebos are given during the same period. Then the patients in study and control groups are switched, Ganoderma Spores Powder Capsules and placebos are given for 6 weeks. The data pertaining to their Life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.

Interventions

OTHERControl group

In control group, only placebos are given for 6 weeks. The patients who are in control groups are switched to receive Ganoderma Spores Powder Capsules for 6 weeks.

DIETARY_SUPPLEMENTGanoderma Spores Powder Capsules

In experimental group, Ganoderma Spores Powder Capsules for 12 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with head-and-neck cancer after complete treatment for at least 3 months (including surgery and/or radiotherapy and/or chemotherapy)

Exclusion criteria

* Patients with head-and-neck cancer under treatment or within 3 months after treatment

Design outcomes

Primary

Measure	Time frame	Description
Immune modulation such as tumor necrosis factors-α or interleukin-6	Change from baseline in cytokines at 6 months	Subjects will be assigned to receive placebo/Ganoderma or Ganoderma Spores Powder Capsules twice a day for 12 weeks. Peripheral blood and saliva will be collected at 3 different times: (1)baseline data: before oral intervention, (2)outcome data: at 6 and 12 weeks post-oral intervention.

Secondary

Measure	Time frame	Description
Life quality	Change from baseline in life quality at 6 months	Health and life quality will assessed by Quality of Life Questionnaire at three different times: (1)baseline data: before intervention, (2)outcome data: at 6 and 12 weeks post-oral intervention.

Countries

Taiwan

Contacts

Primary ContactChing-Yeh Hsiung

hsiungcy@hotmail.com886-975617327

Backup ContactKuender D. Yang

yangkd.yeh@hotmail.com886-975617006

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026